辉瑞公司英文简介
- 格式:ppt
- 大小:2.24 MB
- 文档页数:10
美国辉瑞动物保健品有限公司2010年度猪产品经销商管理方法一、范围、目的1 辉瑞公司(下称“公司”)所有的猪产品经销商2 经销商,作为公司重要的战略合作伙伴,在市场开发、传递产品核心价值、创造客户需求、提升客户生产效益等方面,均发挥着重要的作用。
对此,本制度旨在激励经销商在积极推广辉瑞产品中,求得与公司同步发展、壮大。
3 积极配合辉瑞公司的重点客户和大客户策略,不断提高产品渗透率。
4 鼓励经销商配合公司政策和专业户团队,为所属区属内的二级经销商客户提供最佳服务。
5 鼓励经销商追求卓越,成为当地市场的领导者。
二、经销商责权利1 权利1)执行和享受公司规定的各项政策,提出各种建议。
2)共同参与公司的推广活动和会议。
2 义务1)共同开发市场,维护市场正常的价格体系和客户关系。
2)积极协助公司完成“经销商管理系统”的记录工作。
3)与公司重点客户团队和大客户团队业务人员一起组织客户会议,如各类研讨会等。
按下列标准,共同支付会议费用:三、目标设定1、年度销售目标及季度销售目标,依各位经销商所在地市场之规模大小及潜力、历史销售业绩等不同,由公司认真计算后提出预算。
销售人员与每年年初与经销商进行市场分析,制定销售计划,并确立年度的销售目标。
对于有重点客户或大客户或专业户的区域,目标分开制定,各自单独考核。
2、经销商年度销售目标:是指财政年度内经销商向进口商、山东工厂或苏州工厂(不含税)购买公司指定产品之全年进货金额,所有赠品一律不计入经销商销售业绩,2010年度不包括瑞倍适旺的销售额。
销售目标不但包括全年总金额,还可以包括各产品的销售目标。
第二部分管理一、管理1、经销商应以销售目标为导向配置资源,严格执行公司产品的市场指导价格和配合公司的市场推广策略进行销售,如有特殊情况,应与公司事先书面说明并得到批准。
2、经销商应根据市场的大小和潜力配备足够的业务人员和技术服务人员,以满足共同开发市场的需要。
3、对于同时经营重点客户或大客户或专业户市场的经销商,还须遵守以下规定:1)所有的辉瑞产品二级经销商由推广专员推荐,由区域经理和一级经销商协商决定,有异议的由上级经理确定,最终决定权在猪团队全国销售经理。
About PfizerGood health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we atPfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access tosafe, effective and affordable medicines and related health care services to the people who need them.We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline ofpromising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.To ensure we can continue to deliver on our commitments to the patients,customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions.Through working in partnership with everyone from patients to health careproviders and managed care organizations to world governments andnon-governmental organizations, our goal is to ensure that peopleeverywhere have access to innovative treatments and quality health care.Pfizer OverviewAt Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality,safety and value in the discovery, development and manufacturing ofmedicines for people. Our diversified global health care portfolio includesbiologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer. Every day, Pfizer colleagues all over the world work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 160 years, Pfizer has worked to make a difference for all who rely on us.∙$59 billon in 2012 revenue∙NO.1 Primary CareNO.1 Specialty Care∙10 products with sales greater than $1 billon in 2012∙Over 90,000 colleagues around the world∙59 manufacturing sites worldwide∙Sells products to 150 countries worldwide∙260 R&D partner institutions across the globePfizer History: A Pioneering Spirit on the Frontiers of Medicine∙In 1849, cousins Charles Pfizer and Charles Erhartfounded Charles Pfizer & Company in a red brickbuilding in Brooklyn, NY.∙∙∙The new century brought prosperity to Pfizer. Thepioneering of the mass production of citric acid from sugarthrough mold fermentation fueled growth for years.∙The second half of the 1900's saw intense pharmaceuticalresearch and great successes for Pfizer, which launched aseries of innovative drugs.∙Pfizer increases its global presence through the acquisitions of Warner-Lambertand Pharmacia. Additionally, through strategic partnershipsand acquisitions of diversified businesses, such as Wyeth,Pfizer solidifies its place as one of the most diversifiedcompanies in the global health care industry. Pfizercontinues to focus on applying science and the company'sglobal resources to improve health and well-being at every stage of life.∙Pfizer's Core ValuesPfizer's values distill our core beliefs and the defining features of our culture. Our values reflect the enduring character of Pfizer and its people.Customer Focus: We are deeply committed to meeting the needs of ourcustomers, and we constantly focus on customer satisfaction.Community: We play an active role in making every community in which weoperate a better place to live and work, knowing that its ongoing vitality has adirect impact on the long-term health of our business.Respect for People: We recognize that people are the cornerstone of Pfizer'ssuccess. We value our diversity as a source of strength and are proud of Pfizer's history of treating employees with respect and dignity.Performance: We strive for continuous improvement in our performance,measuring results carefully and ensuring that integrity and respect for people are never compromised.Collaboration: We know that to be a successful company we must worktogether, transcending organizational and geographic boundaries to meet thechanging needs of our customers.Leadership: We believe that leaders empower those around them by sharingknowledge and rewarding outstanding individual effort. We are dedicated toproviding opportunities for leadership at all levels in our organization.Integrity: We demand of ourselves and others the highest ethical standards, and our products and processes will be of the highest quality.Quality: Quality is ingrained in the work of our colleagues and all our Values. We are dedicated to the delivery of quality health care around the world. Ourbusiness practices and processes are designed to achieve quality results thatexceed the expectations of all our stakeholders.Innovation: Innovations is the key to improving health and sustaining Pfizer'sgrowth and profitability.About Pfizer ChinaPfizer has a broad and diversified global product portfolio to improve healthand well-being at every stage of life∙No.1 multinational R&D-based biopharmaceutical company in China∙Over 9000 employees distributed in business, R&D, production and other areas in China∙About $ 1 billon investment in China to date∙2 world class R&D centers in Shanghai and Wuhan∙Business operations over 300 cities∙4 state-of-the-art Manufacturing facilitiesin ChinaPfizer China MilestonesEver since entering the China market in the 1980s, Pfizer has beencommitted to contributing to both the economic development of China and the health of Chinese citizens. We have been continuously offering a broadinnovative product portfolio and actively collaborating with health serviceproviders, academia and governments to support the rapid growth ofhealthcare in China. Our unique competitive advantages enable us to better realize our mission: Working together for a healthier China.1980's Establish a presence in China1989 Dalian Pharmaceutical Plant (1st GMP certificate in China)1991 Suzhou Consumer Health Plant1995 Wuxi Pharmaceutical Plant1997 Beijing Management Center2004 Shanghai Pfizer Investment Co., Ltd.2005 Shanghai China R&D Center2007 Dalian Pfizer Finance Share Service Center (Asia-Pacific)2010 New Research and Development Center in Wuhan2011 Pfizer China reported to Pfizer Corporate directly2012 Pfizer Hisun Pharmaceutical Co., Ltd. (joint-venture)∙Pfizer Business in ChinaWe have introduced more than 50 innovative drugs into China, includingprescription drugs, vaccines and consumer health products which span theareas of cardiovascular, anti-infection, arthritis, oncology, CNS, urology,Vitamins & mineral supplements, calcium supplements…∙Currently market-leading blood fat-lowering medicine Lipitor and hypertensive medicine Norvasc;∙Leading products on treating male erectile dysfunction(ED) Viagra ;∙Leading products in the anti-infective field such as Diflucan, Sulperazon, Zithromax, Tygacil etc.;∙Leading products in the anti-inflammatory analgesic field Celebrex;∙Leading products in the depression field such as Zoloft, Efexor XR etc.;∙Noted brands in the consumer healthcare field such as Caltrate etc.Pfizer's Manufacturing Facilities in ChinaSince the 1980s, Pfizer has established four state-of-the-art plants in Dalian,Suzhou, Wuxi and Fuyang that manufacture products for the pharmaceuticaland consumer healthcare.Pfizer Dalian Pharmaceutical PlantEstablished in 1989, Pfizer Dalian Pharmaceutical Plantis the first GMP-certified plant in China.Pfizer Suzhou Pharmaceutical PlantPfizer Suzhou Pharmaceutical Plant was established in1991 and engages primarily in the production ofconsumer healthcare and other OTC drugs.Pfizer Wuxi Pharmaceutical PlantPfizer Wuxi Pharmaceutical Plant was established in1995 and is a production base for Pfizer China’santi-cancer drugs. The production base becameGMP-certified in 1999.Hisun-Pfizer Pharmaceuticals Co., Ltd.Pfizer established Hisun-Pfizer Pharmaceuticals Co. Ltd. in 2012, The joint venture will develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.。
辉瑞总结引言辉瑞(Pfizer)是一家全球领先的生物制药公司,成立于1849年,总部位于美国纽约,是世界上最重要的制药公司之一。
辉瑞致力于研发、生产和销售药物,为全球医疗健康事业做出了重要贡献。
本文将对辉瑞公司进行总结,并介绍辉瑞在创新药物、合作与并购、社会责任等方面的表现和取得的成就。
创新药物辉瑞在创新药物领域投入巨资,通过持续的研究和开发,不断推出具有重要医疗价值的新药。
辉瑞的核心领域包括癌症、心血管、中枢神经系统等多个治疗领域。
辉瑞的创新药物在临床试验和市场推广中表现出色,在提高患者生活质量和延长寿命方面取得了显著成果。
辉瑞的一项重要创新药物是NewAge。
NewAge是一种针对肺癌的靶向治疗药物,通过针对特定的癌细胞信号通路实现对癌症细胞的选择性杀死,减少对正常细胞的毒副作用。
NewAge在临床试验中表现出较高的总生存率和生存期延长效果,为肺癌患者带来了新的治疗希望。
合作与并购辉瑞通过与其他公司的合作和并购,加强了自身的研发实力和市场竞争力。
辉瑞与多家生物技术公司合作开展创新药物研发,通过共享资源和技术,提高研发效率和成功率。
此外,辉瑞还通过并购方式扩大公司规模和增加产品线。
比如,辉瑞在2016年成功收购了养生堂公司,该公司主要生产保健品和健康食品,这一并购使得辉瑞能够进一步拓展在保健品领域的业务,并通过养生堂的销售渠道增加销售额。
通过合作与并购,辉瑞加强了与其他公司的关系,形成了良好的合作伙伴网络,并且扩大了自身的市场份额和业务范围。
社会责任辉瑞一直注重履行社会责任,积极参与慈善事业和公益活动,为社会健康事业做出了一定贡献。
辉瑞关注全球公共卫生问题,通过捐赠药物和提供医疗援助等方式帮助需要帮助的地区和人群。
例如,辉瑞在西非埃博拉疫情暴发期间,积极提供资金和药物支援,与当地政府合作进行防疫工作,为控制疫情作出了重要贡献。
此外,辉瑞还在教育和科研领域投入资金和资源,支持相关的项目和机构发展,为培养医学人才和促进科学进步做出了贡献。
辉瑞医药发展历程辉瑞医药是一家全球领先的制药公司,扎根于美国。
其发展历程可以追溯到1849年,当年德国药剂师Charles Pfizer在纽约创立了辉瑞公司。
起初,公司主要从事化学产品和医药设备的生产和销售。
随着时间的推移,辉瑞公司逐渐加大了对医药领域的投入,并开始在制药研究和开发方面取得突破。
在20世纪初,辉瑞公司研发出了一种叫作Terramycin的广谱抗生素,这是世界上首个通过发酵法生产的抗生素。
此后,辉瑞公司相继研制出了多种重要药物,包括罗欣、盖希娜、司他夫等,这些药物在医疗领域发挥着重要作用。
在20世纪后半叶,辉瑞公司开始采取战略收购的方式扩大业务。
1999年,辉瑞公司收购了华薄药业公司,进一步加强了其全球制药实力。
此后,辉瑞公司又相继收购了华而草波世(Warner-Lambert)和费尔敏等公司,使公司的产品线更为多元化,市场份额得到了进一步巩固。
辉瑞公司一直致力于创新研发,并在全球范围内建立了大量的研发中心,与各大学和科研机构进行合作。
公司的研发投入始终保持在行业的前沿水平。
此外,辉瑞公司还与联合国儿童基金会合作,开展了多项以寻求解决全球公共卫生问题为目标的项目。
随着时代的发展,辉瑞公司对生物技术药物的研发也越来越重视。
公司在生物制药技术方面取得了重要的突破,并成功研制出了多种生物技术药物,如艾滋病药物Celsentri和肿瘤药物因素。
目前,辉瑞公司已经发展成为全球领先的制药企业,产品涵盖了多个治疗领域,如心血管、神经科学、免疫学等。
公司的使命是通过创新药物研发和提供优质医疗保健解决方案,改善全球人民的生活质量。
辉瑞公司将继续致力于推动医药科技的进步,为人类健康作出更多的贡献。
辉瑞公司辉瑞(Pfizer)公司是一家拥有150多年历史的以研发为基础的跨国制药公司。
辉瑞公司为人类及动物的健康发现、开发、生产和推广各种领先的处方药以及许多世界最驰名的消费产品。
辉瑞公司包括三个业务领域:医药保健、动物保健、以及消费者保健品。
公司的创新产品行销全球150多个国家和地区。
辉瑞制药有限公司拥有世界上最先进的生产设施和检测技术,其一流的检测分析手段及其完美的质量保障体系,使公司的产品全部达到或超过了中国药典和美国药典标准,公司产品获准出口日本、澳大利亚、菲律宾及欧洲等地。
1.3辉瑞公司价值观念为实现辉瑞的目标和完成辉瑞的使命,辉瑞恪守作为辉瑞公司事业成功基础的核心价值观念。
领导人才辉瑞相信领导者通过分享知识和奖励杰出的个人来激励员工。
辉瑞力求为公司内各阶层的员工提供展示其领导才能的机会。
革新创造革新创造是提高健康和保持辉瑞公司持续发展及收益增长的关键。
力争上游辉瑞为持续提高绩效、认真衡量结果及维护道德观念和尊重他人而不懈努力。
尊重他人辉瑞意识到员工是辉瑞成功的基石,多元化的员工队伍是公司力量的源泉,为辉瑞尊重员工的历史而自豪。
团队精神辉瑞深知作为一个成功的公司,辉瑞公司必须团结协作,不断地超越组织结构上及地域上的限制,来满足客户不断变化的需求。
客户至上辉瑞力求满足客户的需求,并以追求客户满意为服务宗旨。
社区精神辉瑞努力在所在的每一个国家及其社区发挥积极作用,使之成为更加美好的生活和工作场所,因为辉瑞所在的国家及其社区的活力对业务长期的健康发展有着直接的影响。
道德观念辉瑞对自己和他人设定崇高的道德标准,并追求完美的产品及高效的运作程序。
追求品质辉瑞致力于为全球提供品质卓越的医疗保健。
辉瑞的业务行为和运作程序都是以获得高品质为目的,超越患者、客户、员工、投资者、商业伙伴和政府官员的期望。
对每一件事,辉瑞追求品质的热忱永无止境。
二、辉瑞在中国二十世纪80年代,伴随着中国改革的发展,辉瑞进入到中国市场,从此开始了长期投身于中国医药卫生事业发展的历程。
辉瑞发展历程
辉瑞(Pfizer)是一家世界知名的跨国药企,总部位于美国纽约。
以下是辉瑞的发展历程:
1849年,辉瑞由德国化学家查尔斯·辉瑞在纽约创立,最初名为“辉瑞化学制药公司”。
1880年,辉瑞开始生产化学品和药品,成为美国最早的药物制造商之一。
1950年,辉瑞推出了溴化锂,作为治疗精神病的药物。
1980年代,辉瑞致力于生物制药领域的研究和开发,并取得了多个重要突破性药物的发现和上市。
1996年,辉瑞推出了世界上第一种“勃起功能障碍”(ED,即阳痿)的口服治疗药物——伟哥(Viagra),这个药物一度成为全球最畅销的药物之一。
2000年,辉瑞宣布收购华美逊(Warner-Lambert),这是历史上最大的制药业并购之一,使辉瑞成为全球最大的药企之一。
2001年,辉瑞推出了针对癌症的重要药物——吉列达(Gleevec),该药物被认为是目前最成功的靶向癌症治疗药物之一,为辉瑞带来了巨大的商业成功。
20世纪末和21世纪初,辉瑞不断进行收购和兼并,扩大了在
全球范围内的市场份额和业务范围。
2019年,辉瑞与辉凌(Myovant)合作开发了一种新型男性避
孕药物,该药物正在进行临床试验。
2020年,辉瑞和德国生物技术公司BioNTech成功合作开发了
一种新型冠状病毒疫苗,该疫苗在全球范围内推出并广泛使用,成为COVID-19疫情防控的重要工具。
辉瑞作为一家创新药企,始终致力于研发和生产高质量和高效药物,并且在全球范围内享有盛誉。